Dynavax Technologies (NASDAQ:DVAX) is a biopharmaceutical company focused on leveraging its proprietary technologies to create immunotherapies. The company's main areas of development include vaccines for infectious diseases, with a significant emphasis on hepatitis B through its HEPLISAV-B vaccine, and oncology through its advanced adjuvant CpG 1018. With an aim to enhance public health globally, Dynavax is committed to discovering and developing innovative vaccines that can address unmet medical needs. The ongoing projects demonstrate the company's dedication to advancing its research and development portfolio, intending to expand its impact on preventing and treating diseases through improved vaccine technology.